search
Back to results

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

Primary Purpose

Fibromyalgia, Sleep, Chronic Pain

Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
eplivanserin (SR46349)
placebo
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Fibromyalgia

Eligibility Criteria

18 Years - 64 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Each patient must fulfill the diagnosis criteria of fibromyalgia according to the American College of Rheumatology Based on patient's information: The patient must complain of unrefreshing sleep for at least 3 nights per week over the past month. The patient spends at least 6.5 hours and not more than 9 hours, in bed, each night over the past 2 weeks. Female patients of childbearing potential must have a confirmed negative pregnancy test at the end of the screening period and use an acceptable method of birth control throughout the study Written, signed and dated informed consent must be obtained from each patient Willing to abstain from taking any medication or treatment prohibited as per the protocol Exclusion Criteria: Females who are lactating or pregnant Night shift workers, and individuals who nap 3 or more times per week over the preceding month (nap: intentionally sleeping for more than 20 minutes during the day). Consumption of beverage with caffeine (i.e. tea, coffee, or cola) comprising more than 2 cups or glasses per day Past or Current medical history of any significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety

Sites / Locations

  • Radiant Research
  • San Diego Arthritis Medical Clinic
  • Jacksonville Center for Clinical Research
  • Miami Research Assoc., Inc.
  • Renstar Medical Research
  • Comprehensive Neuroscience
  • Physicians Research Group
  • Wichita Clinic PA
  • Westroads Medical Group
  • Physicians Research Options
  • Seattle Rheumatology Assoc.
  • Sanofi-Aventis Administrative Office

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

1

2

3

Arm Description

1 mg daily

5 mg daily

Outcomes

Primary Outcome Measures

refreshing quality of sleep measured by the patient sleep questionnaire

Secondary Outcome Measures

sleep parameters (maintenance, duration, induction and quality)

Full Information

First Posted
April 7, 2006
Last Updated
November 29, 2010
Sponsor
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT00313885
Brief Title
Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia
Official Title
Efficacy and Safety of SR46349B (1 and 5mg/Day) Administered During 8 Weeks in Patients With Sleep Disorders in Fibromyalgia: Multi-center, Randomized, Double-blind, Placebo-controlled Study.
Study Type
Interventional

2. Study Status

Record Verification Date
November 2010
Overall Recruitment Status
Completed
Study Start Date
April 2004 (undefined)
Primary Completion Date
June 2005 (Actual)
Study Completion Date
June 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Sanofi

4. Oversight

5. Study Description

Brief Summary
Fibromyalgics frequently report sleep disturbances, in particular poor and unrefreshing sleep. Additionally, studies have reported that sleep problems, pain and mood disturbances are associated in patients with fibromyalgia. By improving the quality of sleep, complaints of poor and unrefreshing sleep, fatigue, pain, which are among the main components of this chronic pain disorder may be improved.
Detailed Description
The purpose of this research study is to investigate the effectiveness and safety of 2 doses of the investigational product in subjects with sleep disorders with fibromyalgia as compared to placebo (a substance which contains no active ingredient). The study will last approximately 70 days and will include 7 office visits.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fibromyalgia, Sleep, Chronic Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
205 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
1 mg daily
Arm Title
2
Arm Type
Experimental
Arm Description
5 mg daily
Arm Title
3
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
eplivanserin (SR46349)
Intervention Description
oral administration
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
oral administration
Primary Outcome Measure Information:
Title
refreshing quality of sleep measured by the patient sleep questionnaire
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
sleep parameters (maintenance, duration, induction and quality)
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Each patient must fulfill the diagnosis criteria of fibromyalgia according to the American College of Rheumatology Based on patient's information: The patient must complain of unrefreshing sleep for at least 3 nights per week over the past month. The patient spends at least 6.5 hours and not more than 9 hours, in bed, each night over the past 2 weeks. Female patients of childbearing potential must have a confirmed negative pregnancy test at the end of the screening period and use an acceptable method of birth control throughout the study Written, signed and dated informed consent must be obtained from each patient Willing to abstain from taking any medication or treatment prohibited as per the protocol Exclusion Criteria: Females who are lactating or pregnant Night shift workers, and individuals who nap 3 or more times per week over the preceding month (nap: intentionally sleeping for more than 20 minutes during the day). Consumption of beverage with caffeine (i.e. tea, coffee, or cola) comprising more than 2 cups or glasses per day Past or Current medical history of any significant, severe, or unstable acute or chronically progressive medical or surgical disorder which may affect patient safety
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ICD CSD
Organizational Affiliation
Sanofi
Official's Role
Study Director
Facility Information:
Facility Name
Radiant Research
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
San Diego Arthritis Medical Clinic
City
San Diego
State/Province
California
ZIP/Postal Code
92108
Country
United States
Facility Name
Jacksonville Center for Clinical Research
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
Miami Research Assoc., Inc.
City
Miami
State/Province
Florida
ZIP/Postal Code
33173
Country
United States
Facility Name
Renstar Medical Research
City
Ocala
State/Province
Florida
ZIP/Postal Code
34471
Country
United States
Facility Name
Comprehensive Neuroscience
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30328
Country
United States
Facility Name
Physicians Research Group
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46250
Country
United States
Facility Name
Wichita Clinic PA
City
Wichita
State/Province
Kansas
ZIP/Postal Code
67208
Country
United States
Facility Name
Westroads Medical Group
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68114
Country
United States
Facility Name
Physicians Research Options
City
Ogden
State/Province
Utah
ZIP/Postal Code
84403
Country
United States
Facility Name
Seattle Rheumatology Assoc.
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104
Country
United States
Facility Name
Sanofi-Aventis Administrative Office
City
Laval
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of SR46349B in Patients With Sleep Disorders in Fibromyalgia

We'll reach out to this number within 24 hrs